The FDA has approved Gelnique (oxybutynin chloride), a gel produced by Watson Pharmaceuticals, to treat symptoms of an overactive bladder. The gel is applied daily to the thigh, abdomen, upper arm or shoulder. Its active ingredient oxybutin chloride is known as an oral drug, but as a gel is it is not metabolized by the liver, which reduces side-effects. During the 12-week trial, that included 789 patients with overactive bladder, Gelnique proved superior to placebo at reducing incontinence episodes and urinary frequency.